{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:09:55Z","timestamp":1791846595566,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HUN-REN-SU Human Microbiota Research Group","award":["No \u201c0272\u201d."],"award-info":[{"award-number":["No \u201c0272\u201d."]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"crossref","award":["J\u00e1nos Bolyai Research Scholarship (BO\/00286\/22\/5)"],"award-info":[{"award-number":["J\u00e1nos Bolyai Research Scholarship (BO\/00286\/22\/5)"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this study delafloxacin resistance mechanisms in\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    strains were analyzed. Delafloxacin is a new fluoroquinolone, that is approved for clinical application however, resistance against this agent is scarcely reported. In our study 37\n                    <jats:italic>E. coli<\/jats:italic>\n                    strains were included and antimicrobial susceptibility testing was performed for ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ceftazidime, cefotaxime, imipenem. Six delafloxacin resistant\n                    <jats:italic>E. coli<\/jats:italic>\n                    strains were selected for whole-genome sequencing and all of them exhibited resistance to other fluoroquinonlones and showed an extended-spectrum beta-lactamase phenotype. The six delafloxacin resistant\n                    <jats:italic>E. coli<\/jats:italic>\n                    strains belonged to different sequence types (STs) namely, ST131 (2 strains), ST57 (2 strains), ST162 and ST15840. Each delafloxacin resistant strain possessed multiple mutations in quinolone resistance-determining regions (QRDRs). Notably, three mutations in\n                    <jats:italic>gyrA<\/jats:italic>\n                    Ser83Leu, Asp87Asn and\n                    <jats:italic>parC<\/jats:italic>\n                    Ser80Ile were in strains of ST162, ST57 and ST15840. However, the two strains of ST131 carried five combined mutations namely,\n                    <jats:italic>gyrA<\/jats:italic>\n                    Ser83Leu, Asp87Asn,\n                    <jats:italic>parC<\/jats:italic>\n                    Ser80Ile, Glu84Val,\n                    <jats:italic>parE<\/jats:italic>\n                    Ile549Leu. Association of delafloxacin resistance and production of CTX-M-15 in ST131, CMY-2 in ST162 and ST15840 was detected. In this study a new ST, ST15840 of clonal complex 69 was identified. Our results demonstrate, that at least three mutations in QRDRs are required for delafloxacin resistance in\n                    <jats:italic>E. coli<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-78124-9","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:02:49Z","timestamp":1730520169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli"],"prefix":"10.1038","volume":"14","author":[{"given":"Andr\u00e1s","family":"Kubicsk\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Kamotsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Kocsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"78124_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1586\/eri.12.110","volume":"10","author":"JDD Pitout","year":"2012","unstructured":"Pitout, J. D. D. Extraintestinal pathogenic Escherichia coli: An update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev. Anti-Infect Ther. 10, 1165\u20131176 (2012).","journal-title":"Expert Rev. Anti-Infect Ther."},{"key":"78124_CR2","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s10096-016-2752-3","volume":"35","author":"V Pascual","year":"2016","unstructured":"Pascual, V. Bloodstream infections caused by Escherichia coli producing AmpC beta-lactamases: Epidemiology and clinical features. Eur. J. Clin. Microbiol. Infect. Dis. 35, 1997\u20132003. https:\/\/doi.org\/10.1007\/s10096-016-2752-3 (2016).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"78124_CR3","doi-asserted-by":"publisher","first-page":"1351618","DOI":"10.3389\/fcimb.2024.1351618","volume":"14","author":"I Garc\u00eda-Meni\u00f1o","year":"2024","unstructured":"Garc\u00eda-Meni\u00f1o, I., Garc\u00eda, V., Lumbreras-Iglesias, P., Fern\u00e1ndez, J. & Mora, A. Fluoroquinolone resistance in complicated urinary tract infections: Association with the increased occurrence and diversity of Escherichia coli of clonal complex 131, together with ST1193. Front. Cell. Infect. Microbiol. 14, 1351618. https:\/\/doi.org\/10.3389\/fcimb.2024.1351618 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"78124_CR4","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1016\/S2666-5247(23)00369-5","volume":"5","author":"N Maldonado","year":"2024","unstructured":"Maldonado, N. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: A multicentre cross-sectional study. Lancet Microbe 5, e390\u2013e399. https:\/\/doi.org\/10.1016\/S2666-5247(23)00369-5 (2024).","journal-title":"Lancet Microbe"},{"key":"78124_CR5","doi-asserted-by":"publisher","first-page":"RP91853","DOI":"10.7554\/eLife.91853","volume":"12","author":"NTK Nhu","year":"2024","unstructured":"Nhu, N. T. K. High-risk Escherichia coli clones that cause neonatal meningitis and association with recrudescent infection. Elife 12, RP91853. https:\/\/doi.org\/10.7554\/eLife.91853 (2024).","journal-title":"Elife"},{"key":"78124_CR6","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3390\/life12122077","volume":"12","author":"B Kocsis","year":"2022","unstructured":"Kocsis, B., Guly\u00e1s, D. & Szab\u00f3, D. Emergence and dissemination of Extraintestinal pathogenic high-risk international clones of Escherichia coli. Life (Basel) 12, 2077. https:\/\/doi.org\/10.3390\/life12122077 (2022).","journal-title":"Life (Basel)"},{"key":"78124_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1128\/CMR.00116-14","volume":"28","author":"AJ Mathers","year":"2015","unstructured":"Mathers, A. J., Peirano, G. & Pitout, J. D. D. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 28, 565\u2013591 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"78124_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini, A. et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 19, 56\u201366 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"78124_CR9","doi-asserted-by":"publisher","first-page":"e00102","DOI":"10.1128\/CMR.00102-19","volume":"33","author":"JDD Pitout","year":"2019","unstructured":"Pitout, J. D. D., Peirano, G., Kock, M. M., Strydom, K. A. & Matsumura, Y. The global ascendency of OXA-48-type carbapenemases. Clin. Microbiol. Rev. 33, e00102\u2013e00119. https:\/\/doi.org\/10.1128\/CMR.00102-19 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"78124_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13756-020-00840-4","volume":"9","author":"J Merida-Vieyra","year":"2020","unstructured":"Merida-Vieyra, J., De Colsa-Ranero, A., Calder\u00f3n-Casta\u00f1eda, Y. & Aquino-Andrade, A. Detection of CMY-type beta-lactamases in Escherichia coli isolates from paediatric patients in a tertiary care hospital in Mexico. Antimicrob. Resist. Infect. Control 9, 168. https:\/\/doi.org\/10.1186\/s13756-020-00840-4 (2020).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"78124_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/mdr.2019.0076","volume":"26","author":"O Dziri","year":"2020","unstructured":"Dziri, O., Dziri, R., Maraoub, A. & Chouchani, C. Characterization of O25b-ST131 Escherichia coli clone producing CTX-M-15, DHA-4, and CMY-42 in urinary tract infections in a Tunisian Island. Microb. Drug Resist. 26, 741\u2013746. https:\/\/doi.org\/10.1089\/mdr.2019.0076 (2020).","journal-title":"Microb. Drug Resist."},{"key":"78124_CR12","doi-asserted-by":"publisher","first-page":"105097","DOI":"10.1016\/j.ebiom.2024.105097","volume":"103","author":"R Zamudio","year":"2024","unstructured":"Zamudio, R. et al. Global transmission of extended-spectrum cephalosporin resistance in Escherichia coli driven by epidemic plasmids. EBioMedicine 103, 105097. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105097 (2024).","journal-title":"EBioMedicine"},{"key":"78124_CR13","doi-asserted-by":"publisher","first-page":"107141","DOI":"10.1016\/j.ijantimicag.2024.107141","volume":"63","author":"H Long","year":"2024","unstructured":"Long, H., Zhao, F., Feng, Y. & Zong, Z. Global distribution of blaCMY-42 a gene mediating reduced susceptibility to aztreonam-avibactam and ceftazidime-avibactam, in Escherichia coli. Int. J. Antimicrob. Agents 63, 107141. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107141 (2024).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"78124_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-024-04769-z","author":"N Helsens","year":"2024","unstructured":"Helsens, N., Sadek, M., Le Terrier, C., Poirel, L. & Nordmann, P. Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type beta-lactamases in PBP3-modified Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. https:\/\/doi.org\/10.1007\/s10096-024-04769-z (2024).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"78124_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.12830","volume":"1354","author":"DC Hooper","year":"2015","unstructured":"Hooper, D. C. & Jacoby, G. A. Mechanisms of drug resistance: Quinolone resistance. Ann. N Y Acad. Sci. 1354, 12\u201331 (2015).","journal-title":"Ann. N Y Acad. Sci."},{"key":"78124_CR16","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1128\/AAC.38.10.2477","volume":"38","author":"J Vila","year":"1994","unstructured":"Vila, J. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38, 2477\u20132479 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(97)07322-4","volume":"351","author":"L Mart\u00ednez-Mart\u00ednez","year":"1998","unstructured":"Mart\u00ednez-Mart\u00ednez, L., Pascual, A. & Jacoby, G. A. Quinolone resistance from a transferable plasmid. Lancet 351, 797\u2013799. https:\/\/doi.org\/10.1016\/S0140-6736(97)07322-4 (1998).","journal-title":"Lancet"},{"key":"78124_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2016.09.001","volume":"29","author":"JM Rodr\u00edguez-Mart\u00ednez","year":"2016","unstructured":"Rodr\u00edguez-Mart\u00ednez, J. M. et al. Plasmid-mediated quinolone resistance: Two decades on. Drug Resist. Update 29, 13\u201329 (2016).","journal-title":"Drug Resist. Update"},{"key":"78124_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/mdr.2018.0245","volume":"25","author":"B Kocsis","year":"2019","unstructured":"Kocsis, B. et al. Ciprofloxacin Promoted qnrD expression and phylogenetic analysis of qnrD harboring plasmids. Microb. Drug Resist. 25, 501\u2013508 (2019).","journal-title":"Microb. Drug Resist."},{"key":"78124_CR20","doi-asserted-by":"crossref","first-page":"e02555","DOI":"10.1128\/AAC.02555-16","volume":"61","author":"E Albornoz","year":"2017","unstructured":"Albornoz, E.  et al. qnrE1, a member of a new famiplasmidllocatedocated quinolone resisgenes goriginatedinated frochromosomemosome of enterobspeciespecies. Antimicrob. Agents Chemother. 61, e02555\u2013e02516 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR21","doi-asserted-by":"publisher","first-page":"e0045621","DOI":"10.1128\/AAC.00456-21","volume":"65","author":"C Wang","year":"2021","unstructured":"Wang, C., Yin, M., Zhang, X., Guo, Q. & Wang, M. qnrE3 and qnrE4, new transferable quinolone resistance qnre family genes originating from enterobacter mori and enterobacter asburiae, respectively. Antimicrob. Agents Chemother 65, e0045621 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR22","doi-asserted-by":"publisher","first-page":"102392","DOI":"10.1016\/j.plasmid.2018.12.001","volume":"118","author":"A Carattoli","year":"2021","unstructured":"Carattoli, A., Villa, L., Fortini, D. & Garc\u00eda-Fern\u00e1ndez, A. Contemporary IncI1 plasmids involved in the transmission and spread of antimicrobial resistance in Enterobacteriaceae. Plasmid 118, 102392. https:\/\/doi.org\/10.1016\/j.plasmid.2018.12.001 (2021).","journal-title":"Plasmid"},{"key":"78124_CR23","doi-asserted-by":"publisher","first-page":"30589","DOI":"10.2807\/1560-7917.ES.2017.22.31.30589","volume":"22","author":"A Carattoli","year":"2021","unstructured":"Carattoli, A. et al. Novel plasmid-mediated colistin resistance mcr-4 gene in Salmonella and Escherichia coli, Italy 2013, Spain and Belgium, 2015 to 2016. Euro. Surveill 22, 30589. https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.31.30589 (2017).","journal-title":"Euro. Surveill"},{"key":"78124_CR24","doi-asserted-by":"publisher","first-page":"32281","DOI":"10.1038\/srep32281","volume":"6","author":"CY Kao","year":"2016","unstructured":"Kao, C. Y. Plasmid-mediated quinolone resistance determinants in quinolone-resistant Escherichia coli isolated from patients with bacteremia in a university hospital in Taiwan, 2001\u20132015. Sci. Rep. 6, 32281. https:\/\/doi.org\/10.1038\/srep32281 (2016).","journal-title":"Sci. Rep."},{"key":"78124_CR25","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/antibiotics10121506","volume":"10","author":"B Kocsis","year":"2021","unstructured":"Kocsis, B., Guly\u00e1s, D. & Szab\u00f3, D. Delafloxacin, finafloxacin, and zabofloxacin: Novel fluoroquinolones in the antibiotic pipeline. Antibiot. (Basel) 10, 1506. https:\/\/doi.org\/10.3390\/antibiotics10121506 (2021).","journal-title":"Antibiot. (Basel)"},{"key":"78124_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","volume":"15","author":"B Kocsis","year":"2016","unstructured":"Kocsis, B., Domokos, J. & Szabo, D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann. Clin. Microbiol. Antimicrob. 15, 34. https:\/\/doi.org\/10.1186\/s12941-016-0150-4 (2016).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"78124_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","volume":"15","author":"A Rusu","year":"2023","unstructured":"Rusu, A., Munteanu, A. C.,  Arb\u0103na\u0219i, E. M. & Uivarosi, V. Overview of side-effects of antibacterial fluoroquinolones: New drugs versus old drugs, a step forward in the safety profile? Pharmaceutics 15, 804 (2023). https:\/\/doi.org\/10.3390\/pharmaceutics15030804","journal-title":"Pharmaceutics"},{"key":"78124_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jac\/dkx543","volume":"73","author":"BT Mogle","year":"2018","unstructured":"Mogle, B. T., Steele, J. M., Thomas, S. J., Bohan, K. H. & Kufel, W. D. Clinical review of delafloxacin: A novel anionic fluoroquinolone. J. Antimicrob. Chemother. 73, 1439\u20131451. https:\/\/doi.org\/10.1093\/jac\/dkx543 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"78124_CR29","first-page":"e02803","volume":"62","author":"MA Pfaller","year":"2018","unstructured":"Pfaller, M. A., Sader, H. S., Rhomberg, P. R. & Flamm, R. K. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob. Agents Chemother. 62, e02803\u2013e02817 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR30","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1128\/AAC.02798-15","volume":"60","author":"OO Soge","year":"2016","unstructured":"Soge, O. O., Salipante, S. J., No, D., Duffy, E. & Roberts, M. C. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob. Agents Chemother. 60, 3106\u20133111. https:\/\/doi.org\/10.1128\/AAC.02798-15 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR31","doi-asserted-by":"publisher","first-page":"114980","DOI":"10.1016\/j.diagmicrobio.2019.114980","volume":"96","author":"L Boyanova","year":"2020","unstructured":"Boyanova, L., Markovska, R., Medeiros, J., Gergova, G. & Mitov, I. Delafloxacin against Helicobacter pylori, a potential option for improving eradication success? Diagn. Microbiol. Infect. Dis. 96, 114980. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114980 (2020).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"78124_CR32","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/AAC.00181-13","volume":"57","author":"J Bauer","year":"2013","unstructured":"Bauer, J., Siala, W., Tulkens, P. M. & Bambeke, V. F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57, 2726\u20132737 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14787210.2018.148972","volume":"16","author":"ER Ocheretyaner","year":"2018","unstructured":"Ocheretyaner, E. R. & Park, T. E. Delafloxacin: A novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Rev. Anti Infect. Ther. 16, 523\u2013530. https:\/\/doi.org\/10.1080\/14787210.2018.148972 (2018).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"78124_CR34","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/microorganisms11061602","volume":"11","author":"D Guly\u00e1s","year":"2023","unstructured":"Guly\u00e1s, D., Kamotsay, K., Szab\u00f3, D. & Kocsis, B. Investigation of delafloxacin resistance in multidrug-resistant Escherichia coli strains and the detection of E. Coli ST43 international high-risk clone. Microorganisms 11, 1602. https:\/\/doi.org\/10.3390\/microorganisms11061602 (2023).","journal-title":"Microorganisms"},{"key":"78124_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","volume":"73","author":"MS Butler","year":"2020","unstructured":"Butler, M. S. & Paterson, D. L. Antibiotics in the clinical pipeline in October 2019. J. Antibiot. (Tokyo) 73, 329\u2013364. https:\/\/doi.org\/10.1038\/s41429-020-0291-8 (2020).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"78124_CR36","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1093\/jac\/dkae269","volume":"79","author":"V Luzarraga","year":"2024","unstructured":"Luzarraga, V. et al. In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates. J. Antimicrob. Chemother. 79, 2633\u20132639. https:\/\/doi.org\/10.1093\/jac\/dkae269 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"78124_CR37","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/cid\/ciz787","volume":"70","author":"I Alejandro","year":"2020","unstructured":"Alejandro, I., Zeb, K., Saquib, M., David, L. & John, Q. Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York. Clin. Infect. Dis. 70, 1758\u20131760. https:\/\/doi.org\/10.1093\/cid\/ciz787 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"78124_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0732-8893(03)00037-3","volume":"46","author":"H Toshinobu","year":"2003","unstructured":"Toshinobu, H. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: Effects of the mutations on fluoroquinolone MICs. Diagn. Microbiol. Infect. Dis. 46, 139\u2013145. https:\/\/doi.org\/10.1016\/S0732-8893(03)00037-3 (2003).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"78124_CR39","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","volume":"67","author":"JM Remy","year":"2012","unstructured":"Remy, J. M., Tow-Keogh, C. A., McConnell, T. S., Dalton, J. M. & DeVito, J. A. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization. J. Antimicrob. Chemother. 67, 2814\u20132820. https:\/\/doi.org\/10.1093\/jac\/dks307 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"78124_CR40","doi-asserted-by":"publisher","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","volume":"61","author":"S McCurdy","year":"2017","unstructured":"McCurdy, S. Vitro Activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolatestwoophase phstudiestudies of bacterialtskinl skiskindstructureuinfectionsctions. Antimicrob. Agents Chemother. 61, e00772\u2013e00717. https:\/\/doi.org\/10.1128\/AAC.00772-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78124_CR41","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/antibiotics12081241","volume":"12","author":"A Turban","year":"2023","unstructured":"Turban, A., Fran\u00e7ois, G., Aur\u00e9lien, D. & Vincent, C. Updated review on clinically-relevant properties of delafloxacin. Antibiotics 12, 1241. https:\/\/doi.org\/10.3390\/antibiotics12081241 (2023).","journal-title":"Antibiotics"},{"key":"78124_CR42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/jac\/dkn206","volume":"62","author":"D Szab\u00f3","year":"2008","unstructured":"Szab\u00f3, D. et al. First detection of plasmid-mediated, quinolone resistance determinants qnrA, qnrB, qnrS and Aac(6\u2019)-Ib-cr in extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary. J. Antimicrob. Chemother. 62, 630\u2013632. https:\/\/doi.org\/10.1093\/jac\/dkn206 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"78124_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1556\/030.65.2018.012","volume":"65","author":"O Szab\u00f3","year":"2018","unstructured":"Szab\u00f3, O. Plasmid-mediated quinolone resistance determinants in Enterobacteriaceae from urine clinical samples. Acta Microbiol. Immunol. Hung. 65, 255\u2013265. https:\/\/doi.org\/10.1556\/030.65.2018.012 (2018).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"78124_CR44","doi-asserted-by":"publisher","unstructured":"Markovska, R. et al. Dissemination of high-risk clones Enterobacterales among Bulgarian fecal carriage isolates. Microorganisms 10 (2144). https:\/\/doi.org\/10.3390\/microorganisms10112144 (2022).","DOI":"10.3390\/microorganisms10112144"},{"key":"78124_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/mdr.2022.0254","volume":"29","author":"A Labid","year":"2023","unstructured":"Labid, A. Antimicrobial Resistance among Gram-negative Bacteria isolated in the Newborn Intensive Care Unit at Abderrezak-Bouhara Hospital of Skikda, Algeria. Microb. Drug Resist. 29, 229\u2013238. https:\/\/doi.org\/10.1089\/mdr.2022.0254 (2023).","journal-title":"Microb. Drug Resist."},{"key":"78124_CR46","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3201\/eid2805.212535","volume":"28","author":"G Peirano","year":"2022","unstructured":"Peirano, G. Genomic epidemiology of global carbapenemase-producing Escherichia coli, 2015\u20132017. Emerg. Infect. Dis. 28, 924\u2013931. https:\/\/doi.org\/10.3201\/eid2805.212535 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"78124_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1556\/030.2023.02120","volume":"70","author":"A Romdhani","year":"2023","unstructured":"Romdhani, A. High-risk clonal lineages among extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae from urban and rural stagnant water samples in Tunisia. Acta Microbiol. Immunol. Hung. 70, 304\u2013310. https:\/\/doi.org\/10.1556\/030.2023.02120 (2023).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"78124_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2147\/IDR.S427571","volume":"17","author":"L Wang","year":"2024","unstructured":"Wang, L. Whole-genome sequencing of an Escherichia coli ST69 strain harboring blaCTX-M-27 on a hybrid plasmid. Infect Drug Resist 17, 365\u2013375. https:\/\/doi.org\/10.2147\/IDR.S427571 (2024).","journal-title":"Infect Drug Resist"},{"key":"78124_CR49","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/antibiotics12101519","volume":"12","author":"A Szmolka","year":"2023","unstructured":"Szmolka, A. et. al. Emergence and genomic features of a mcr-1 Escherichia coli from duck in Hungary. Antibiot. (Basel) 12, 1519. https:\/\/doi.org\/10.3390\/antibiotics12101519 (2023).","journal-title":"Antibiot. (Basel)"},{"key":"78124_CR50","doi-asserted-by":"publisher","first-page":"785411","DOI":"10.3389\/fmicb.2021.785411","volume":"12","author":"BJ Nagy","year":"2022","unstructured":"Nagy, B. J. Comparison of extended-spectrum beta-lactamase-producing Escherichia coli isolates from Rooks (Corvus frugilegus) and contemporary human-derived strains: A one health perspective. Front. Microbiol. 12, 785411. https:\/\/doi.org\/10.3389\/fmicb.2021.785411 (2022).","journal-title":"Front. Microbiol."},{"key":"78124_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antibiotics13010031","volume":"13","author":"Z Garba","year":"2023","unstructured":"Garba, Z. Phenotypic detection of Carbapenemase and AmpC-beta-lactamase production among extended spectrum beta-lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from clinical specimens. Antibiot. (Basel) 13, 31. https:\/\/doi.org\/10.3390\/antibiotics13010031 (2023).","journal-title":"Antibiot. (Basel)"},{"key":"78124_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12866-023-03108-0","volume":"23","author":"Z Garba","year":"2023","unstructured":"Garba, Z. Wastewater from healthcare centers in Burkina Faso is a source of ESBL, AmpC-beta-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae. BMC Microbiol. 23, 351. https:\/\/doi.org\/10.1186\/s12866-023-03108-0 (2023).","journal-title":"BMC Microbiol."},{"key":"78124_CR53","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41598-022-14177-y","volume":"12","author":"A Lindblom","year":"2022","unstructured":"Lindblom, A. et al. The impact of the ST131 clone on recurrent ESBL-producing E. Coli urinary tract infection: A prospective comparative study. Sci. Rep. 12, 10048. https:\/\/doi.org\/10.1038\/s41598-022-14177-y (2022).","journal-title":"Sci. Rep."},{"key":"78124_CR54","doi-asserted-by":"publisher","first-page":"2400073","DOI":"10.2807\/1560-7917.ES.2024.29.8.2400073","volume":"29","author":"A Piazza","year":"2024","unstructured":"Piazza, A. Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023. Euro Surveill. 29, 2400073. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.8.2400073 (2024).","journal-title":"Euro Surveill."},{"key":"78124_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1556\/030.2022.01889","volume":"70","author":"DK Er","year":"2022","unstructured":"Er, D. K., D\u00fcndar, D. & Uzuner, H. Distribution of virulence determinants among Escherichia coli ST131 and its H30\/H30-Rx subclones in Turkey. Acta Microbiol. Immunol. Hung. 70, 47\u201351. https:\/\/doi.org\/10.1556\/030.2022.01889 (2022).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"78124_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1556\/AMicr.60.2013.2.8","volume":"60","author":"A T\u00f3th","year":"2013","unstructured":"T\u00f3th, A. Characterization of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli strains isolated from animal and human clinical samples in Hungary in 2006\u20132007. Acta Microbiol. Immunol. Hung. 60, 175\u2013185 (2013).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"78124_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12941-022-00493-8","volume":"21","author":"K T\u00f3th","year":"2022","unstructured":"T\u00f3th, K., T\u00f3th, \u00c1., Kamotsay, K., N\u00e9meth, V. & Szab\u00f3, D. Population snapshot of the extended-spectrum beta-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital. Ann. Clin. Microbiol. Antimicrob. 21, 3. https:\/\/doi.org\/10.1186\/s12941-022-00493-8 (2022).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"78124_CR58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/antibiotics13040363","volume":"13","author":"K T\u00f3th","year":"2024","unstructured":"T\u00f3th, K. Genomic epidemiology of C2\/H30Rx and C1-M27 subclades of Escherichia coli ST131 isolates from clinical blood samples in Hungary. Antibiot. (Basel) 13, 363. https:\/\/doi.org\/10.3390\/antibiotics13040363 (2024).","journal-title":"Antibiot. (Basel)"},{"key":"78124_CR59","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3389\/fmicb.2016.01017","volume":"7","author":"M Fuzi","year":"2016","unstructured":"Fuzi, M. Dissimilar fitness associated with resistance to fluoroquinolones influences Clonal dynamics of various multiresistant bacteria. Front. Microbiol. 7, 1017. https:\/\/doi.org\/10.3389\/fmicb.2016.01017 (2016).","journal-title":"Front. Microbiol."},{"key":"78124_CR60","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3389\/fmicb.2017.02261","volume":"8","author":"M Fuzi","year":"2017","unstructured":"Fuzi, M., Szabo, D. & Csercsik, R. Double-serine fluoroquinolone resistance mutations advance major international clones and lineages of various multi-drug resistant bacteria. Front. Microbiol 8, 2261. https:\/\/doi.org\/10.3389\/fmicb.2017.02261 (2017).","journal-title":"Front. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78124-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78124-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78124-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:03:12Z","timestamp":1730520192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78124-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78124"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78124-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26423"}}